Silence Therapeutics SLN offering and merger news

Opinion · Devil's advocate

Fact-check-o-meter

Silence's 'potential best-in-class' label rests on 48 patients and a cross-trial comparison

Silence's phase 2 numbers match the registry design, and its legal record is clean. The gaps are in framing: 'potential best-in-class' is asserted from a small placebo-controlled study with no head-to-head data against an approved weekly drug, and the October merger release describes a sale process that the 8-K does not describe.

1. Science · weight medium

   'Potential best-in-class' from a 48-patient trial with no head-to-head data

   The company said: "Trial met its primary endpoint, with a significantly higher proportion of clinical responders on divesiran (88%) compared to placebo (19%); placebo-adjusted response rate = 69%" source

   The record says: The release describes SANRECO as "randomized, placebo-controlled, double-blind" in "48 phlebotomy-dependent PV patients," with a primary endpoint measured in weeks 18 to 36. ClinicalTrials.gov lists NCT05499013 as a Phase 1/2 study of 69 participants with a Phase 2 primary outcome of response "between week 18 and week 36." Takeda's rusfertide, approved on August 28, 2026, reports 76.9% response in "Weeks 20-32" with once-weekly dosing, under a differently worded phlebotomy-eligibility definition. source

   Our view: The placebo-controlled result is real and the design is sound. But the response windows and definitions differ from the approved comparator, so 'potential best-in-class' is a hypothesis, not a finding. Safety rests on 48 patients for 36 weeks, with the long-term extension still blinded.

2. Press release vs filing · weight low

   Runway statement sits in the 10-Q, not the results release, and a raise followed the same day

   The company said: "Cash Position: Cash and cash equivalents were $72.1 million as of June 30, 2026." source

   The record says: The 10-Q says cash "will be sufficient to fund our anticipated operating and capital expenditure requirements into 2028" and also "The Group will need to raise additional funding to fund its operating expenses and capital expenditure requirements in relation to its clinical development activities." On the same day, August 10, Silence announced "an underwritten public offering of approximately $150 million." The final prospectus supplement filed August 12 covers 12,962,963 ADSs at $13.50 each, about $175 million. The final prospectus supplement filed August 12 covers 12,962,963 ADSs at $13.50 each, about $175 million. The final prospectus supplement filed August 12 covers 12,962,963 ADSs at $13.50 each, about $175 million. The final prospectus supplement filed August 12 covers 12,962,963 ADSs at $13.50 each, about $175 million. The final prospectus supplement filed August 12 covers 12,962,963 ADSs at $13.50 each, about $175 million. The final prospectus supplement filed August 12 covers 12,962,963 ADSs at $13.50 each, about $175 million. source

   Our view: The results release gave the cash figure without a runway estimate. The filing's 'into 2028' view excludes any new financing and excludes unachieved milestones, per the going-concern note, and the company raised money almost immediately. Nothing is contradicted, but the sequence matters to existing holders.

3. Press release vs filing · weight medium

   Merger release cites a competitive process; the 8-K does not describe it

   The company said: "the result of a competitive sale process and delivers significant, immediate and certain value to our shareholders" source

   The record says: The 8-K filed for the same deal sets out the terms: a scheme of arrangement needing shareholder approval at 75% in value, High Court sanction and regulatory approvals, a $13 million termination fee payable by Silence in certain circumstances, and voting support from holders of about 14% of voting power. It does not give a background of the sale process. source

   Our view: The process claim is the company's description. A fuller history will normally appear in the scheme documents. Separately, and with no link stated in either filing, the 10-Q disclosed that the former chief executive left under a July 2026 separation agreement that extended change-in-control treatment of unvested options to December 14, 2026, valued at $1.4 million.

4. Legal and disclosure record · weight low

   No material legal proceedings disclosed

   The record says: Item 1, Legal Proceedings: "We are not party to any material legal proceedings at this time." source

   Our view: No securities litigation or enforcement disclosed in the latest filing. The October 8-K was filed after the 10-Q and we found no litigation mentioned in it.

This is opinion. We compare the company's own announcements with its filings and the scientific record, and link every source. It is not an allegation of wrongdoing and not investment or legal advice. Legal items list only matters disclosed in filings or by courts and regulators. Checked Oct 23, 2026. Companies can respond through our right of reply.